CU20140132A7 - Métodos de quelatos de oligonucleótidos - Google Patents

Métodos de quelatos de oligonucleótidos

Info

Publication number
CU20140132A7
CU20140132A7 CU2014000132A CU20140132A CU20140132A7 CU 20140132 A7 CU20140132 A7 CU 20140132A7 CU 2014000132 A CU2014000132 A CU 2014000132A CU 20140132 A CU20140132 A CU 20140132A CU 20140132 A7 CU20140132 A7 CU 20140132A7
Authority
CU
Cuba
Prior art keywords
chelates
oligonucleotide
methods
hypertriglyceridemia
hypercholesterolemia
Prior art date
Application number
CU2014000132A
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of CU20140132A7 publication Critical patent/CU20140132A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)

Abstract

Se describen composiciones farmacéuticas y métodos para el tratamiento de infecciones virales, hipercolesterolemia, hipertrigliceridemia, Alzheimer, enfermedades causadas por priones y distrofia muscular de Duchenne con quelatos de oligonucleótidos.
CU2014000132A 2012-05-18 2014-11-17 Métodos de quelatos de oligonucleótidos CU20140132A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648694P 2012-05-18 2012-05-18
PCT/CA2013/050378 WO2013170385A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex methods

Publications (1)

Publication Number Publication Date
CU20140132A7 true CU20140132A7 (es) 2015-02-26

Family

ID=49581827

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2014000132A CU20140132A7 (es) 2012-05-18 2014-11-17 Métodos de quelatos de oligonucleótidos

Country Status (37)

Country Link
US (1) US9616083B2 (es)
EP (1) EP2849760B1 (es)
JP (2) JP6294308B2 (es)
KR (1) KR101975915B1 (es)
CN (1) CN104379152B (es)
AR (1) AR091065A1 (es)
AU (1) AU2013262415B2 (es)
BR (1) BR112014028568B1 (es)
CA (1) CA2873526C (es)
CL (1) CL2014003135A1 (es)
CO (1) CO7131388A2 (es)
CR (1) CR20140522A (es)
CU (1) CU20140132A7 (es)
CY (1) CY1122856T1 (es)
DK (1) DK2849760T3 (es)
DO (1) DOP2014000263A (es)
EA (1) EA034799B1 (es)
EC (1) ECSP14027542A (es)
ES (1) ES2767333T3 (es)
HR (1) HRP20200045T1 (es)
HU (1) HUE047456T2 (es)
IL (1) IL235402B (es)
IN (1) IN2014DN08982A (es)
LT (1) LT2849760T (es)
MX (1) MX360626B (es)
MY (1) MY168209A (es)
NZ (1) NZ701931A (es)
PH (1) PH12014502484B1 (es)
PL (1) PL2849760T3 (es)
PT (1) PT2849760T (es)
RS (1) RS59914B1 (es)
SG (1) SG11201407261XA (es)
SI (1) SI2849760T1 (es)
SM (1) SMT202000025T1 (es)
TW (1) TWI648288B (es)
WO (1) WO2013170385A1 (es)
ZA (1) ZA201408082B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2203173T3 (en) 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
ES2907250T3 (es) 2012-01-27 2022-04-22 Biomarin Tech Bv Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
NZ705730A (en) 2012-08-30 2016-06-24 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
AU2015286199B2 (en) * 2014-07-10 2020-05-14 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D virus infections
KR102401252B1 (ko) 2015-04-23 2022-05-24 제론 코포레이션 다가 양이온 염 조성물을 사용한 폴리뉴클레오티드 제조의 방법
EP4279084B1 (en) 2015-10-28 2025-06-11 Vertex Pharmaceuticals Inc. Materials and methods for treatment of duchenne muscular dystrophy
JP7412079B2 (ja) * 2015-12-23 2024-01-12 レプルカ プロプライアタリー リミティド 核酸オリゴマーとその用途
CN109757108A (zh) * 2016-07-05 2019-05-14 比奥马林技术公司 具有治疗遗传疾病的改善特征的包含双环支架部分的前体mRNA剪接转换或调节寡核苷酸
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218372T1 (de) * 1993-04-01 2002-06-15 Isis Pharmaceuticals Inc Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
US20020166764A1 (en) * 1997-08-12 2002-11-14 University Of Southern California Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN1694959A (zh) * 2002-09-13 2005-11-09 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
AU2003267785C1 (en) * 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
JP2008516996A (ja) * 2004-10-19 2008-05-22 レプリコール インコーポレーティッド 抗ウイルス性オリゴヌクレオチド
CA2624686A1 (en) 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
US8101585B2 (en) * 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010107838A1 (en) * 2009-03-16 2010-09-23 Isis Pharmaceuticals, Inc. Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
WO2010138806A2 (en) * 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
SG187165A1 (en) 2010-08-20 2013-02-28 Replicor Inc Oligonucleotide chelate complexes

Also Published As

Publication number Publication date
IL235402B (en) 2022-01-01
IN2014DN08982A (es) 2015-05-22
US20130310445A1 (en) 2013-11-21
EA201401276A1 (ru) 2015-04-30
EP2849760A1 (en) 2015-03-25
HUE047456T2 (hu) 2020-04-28
CA2873526C (en) 2020-08-18
DK2849760T3 (da) 2020-02-03
US9616083B2 (en) 2017-04-11
PL2849760T3 (pl) 2020-05-18
JP6294308B2 (ja) 2018-03-14
EP2849760A4 (en) 2015-03-25
NZ701931A (en) 2016-06-24
MX2014013885A (es) 2015-05-08
CO7131388A2 (es) 2014-12-01
PT2849760T (pt) 2020-01-24
JP2018058853A (ja) 2018-04-12
HRP20200045T1 (hr) 2020-03-20
CL2014003135A1 (es) 2015-01-09
CR20140522A (es) 2014-12-10
AU2013262415A1 (en) 2014-11-27
LT2849760T (lt) 2020-04-10
SG11201407261XA (en) 2014-12-30
BR112014028568B1 (pt) 2022-02-15
CA2873526A1 (en) 2013-11-21
AR091065A1 (es) 2014-12-30
PH12014502484A1 (en) 2015-01-12
JP2015517503A (ja) 2015-06-22
SI2849760T1 (sl) 2020-03-31
PH12014502484B1 (en) 2021-03-31
CN104379152B (zh) 2018-10-30
RS59914B1 (sr) 2020-03-31
EA034799B1 (ru) 2020-03-23
DOP2014000263A (es) 2015-01-31
BR112014028568A2 (pt) 2020-06-02
CN104379152A (zh) 2015-02-25
HK1206259A1 (en) 2016-01-08
IL235402A0 (en) 2014-12-31
MY168209A (en) 2018-10-15
ZA201408082B (en) 2015-12-23
WO2013170385A1 (en) 2013-11-21
ES2767333T3 (es) 2020-06-17
CY1122856T1 (el) 2021-05-05
TWI648288B (zh) 2019-01-21
KR101975915B1 (ko) 2019-05-08
ECSP14027542A (es) 2015-12-31
EP2849760B1 (en) 2019-10-30
MX360626B (es) 2018-11-12
KR20150016330A (ko) 2015-02-11
AU2013262415B2 (en) 2017-06-22
TW201408689A (zh) 2014-03-01
SMT202000025T1 (it) 2020-03-13

Similar Documents

Publication Publication Date Title
DOP2014000263A (es) Métodos de quelatos de oligonucleótidos
CL2015001358A1 (es) Potenciadores del cftr deuterados
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
BR112015022674A2 (pt) inibidores de bromodomínio
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
CL2015000942A1 (es) Compuestos de benceno sustituido.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
PH12016500492B1 (en) Pyridazinone compounds and uses thereof
EP2841107A4 (en) CYTOTOXIC ACTIVITIES DISPOSED OF HIV RELEASING MOLECULES (CDM-HS), CYTOTOXIC EFFECT AGAINST HUMAN IMMUNE WEAKAGE VIRUS AND METHOD OF USE
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
BR112015014145A2 (pt) compostos antibacterianos
BR112014009217A2 (pt) antibacterianos à base de fenicol